Cambridge Epigenetix Licenses Fundamental DNA Methylation IP from Boston Children’s Hospital

Product News   Apr 28, 2017 | Original story from Cambridge Epigenetix

 
Cambridge Epigenetix Licenses Fundamental DNA Methylation IP from Boston Children’s Hospital

Anjana Rao. Credit: Cambridge Epigenetix

 
 
FURTHER INFORMATION
 
 
 

Related Product News

Horizon Introduces Four BRAF Resistant Melanoma PDX Models

Product News

PDX models of tumors offer better in vivo insights for cancer research and drug development.

READ MORE

Pushing Forward Hybridisation-based Targeted Sequencing

Product News

OGT’s unique hybridisation expertise takes researchers from sample to sequencer in a single day.

READ MORE

Thermo Introduces the Latest in Capillary Electrophoresis Technology

Product News

New low-throughput Sanger sequencing and fragment analysis platform offers trusted technology and workflow with all-in-one cartridge system and cloud connectivity.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research Diagnostics Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE